{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T04:17:47Z","timestamp":1787026667890,"version":"build-2736575974"},"reference-count":16,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:00:00Z","timestamp":1739750400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:p>Generalized pustular psoriasis (GPP) is a rare and potentially life-threatening autoimmune inflammatory skin disease. Tofacitinib is a non-selective, first-generation Janus kinase (JAK) inhibitor. Currently, both domestic and international reports regarding the use of tofacitinib mainly have primarily focused on the treatment of psoriasis vulgaris and psoriatic arthritis. As GPP is a rare skin disease, reports on the use of tofacitinib in the treatment of GPP are rare. This report presents a case of severe GPP that was effectively treated with tofacitinib. This case suggests that this non-selective JAK inhibitor, which has strong anti-inflammatory effects, could serve as an effective treatment option for cases of acute exacerbation of GPP, with a good safety profile.<\/jats:p>","DOI":"10.3389\/fmed.2025.1518583","type":"journal-article","created":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:12:36Z","timestamp":1739751156000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["Case report: Efficacy of tofacitinib in the treatment of generalized pustular psoriasis"],"prefix":"10.3389","volume":"12","author":[{"given":"Xian","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,2,17]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1111\/exd.14765","article-title":"Current management of generalized pustular psoriasis","volume":"32","author":"Kodali","year":"2023","journal-title":"Exp Dermatol"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"378","DOI":"10.25259\/IJDVL_1054_2021","article-title":"Correlation of IL36RN and CARD14 mutations with clinical manifestations and laboratory findings in patients with generalised pustular psoriasis","volume":"89","author":"Trai","year":"2023","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"335","DOI":"10.13735\/j.cjdv.1001-7089.202211080","article-title":"Research Progress on the role of IL-23\/IL-17\/IL-36 immune axis in the pathogenesis and treatment of psoriasis","volume":"38","author":"Wencheng","year":"2024","journal-title":"Chin J Dermatol Venereol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1111\/exd.14768","article-title":"Pathophysiology of generalized pustular psoriasis","volume":"32","author":"Young","year":"2023","journal-title":"Exp Dermatol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"602","DOI":"10.1684\/ejd.2021.4047","article-title":"Update on the aetiology and mechanisms of generalized pustular psoriasis","volume":"31","author":"Wang","year":"2021","journal-title":"Eur J Dermatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"668","DOI":"10.55563\/clinexprheumatol\/e7ayu8","article-title":"JAK\/STAT pathway and nociceptive cytokine signalling in rheumatoid arthritis and psoriatic arthritis","volume":"39","author":"Crispino","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"7897263","DOI":"10.1155\/2018\/7897263","article-title":"Selective immunomodulation of inflammatory pathways in keratinocytes by the Janus kinase (JAK) inhibitor tofacitinib: implications for the employ ment of JAK-targeting drugs in psoriasis","volume":"2018","author":"Morelli","year":"2018","journal-title":"J Immunol Res"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.pupt.2017.01.002","article-title":"Tofacitinib ameliorates inflammation in a rat model of airway neutrophilia induced by inhaled LPS","volume":"43","author":"Calama","year":"2017","journal-title":"Pulm Pharmacol Ther"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.3389\/fimmu.2020.01406","article-title":"Monocyte-derived dendritic cell differentiation in inflammatory arthritis is regulated by the JAK\/STAT axis via NADPH oxidase regulation","volume":"11","author":"Marzaioli","year":"2020","journal-title":"Front Immunol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"1301123","DOI":"10.3389\/fmed.2023.1301123","article-title":"Successful treatment of nail lichen planus with tofacitinib: a case report and review of the literature","volume":"10","author":"Huang","year":"2023","journal-title":"Front Med"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1053\/j.gastro.2020.01.001","article-title":"Safety of Janus kinase inhibitors in patients with inflammatory bowel diseases or other immune-mediated diseases: a systematic review and Meta-analysis","volume":"158","author":"Olivera","year":"2020","journal-title":"Gastroenterology"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"e70196","DOI":"10.7759\/cureus.70196","article-title":"Assessment of the safety of Tofacitinib among patients with psoriasis: a systematic review and Meta-analysis","volume":"16","author":"Alqahtani","year":"2024","journal-title":"Cureus"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1007\/s10067-024-06940-5","article-title":"Efficacy and safety of tofacitinib for chronic plaque psoriasis and psoriatic arthritis: a systematic review and meta-analysis of randomized controlled trials","volume":"43","author":"Dai","year":"2024","journal-title":"Clin Rheumatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"98","DOI":"10.4103\/ijdd.ijdd_23_22","article-title":"Novel use of tofacitinib in the recalcitrant adult generalized pustular psoriasis","volume":"8","author":"Shreya","year":"2022","journal-title":"Ind J Drugs Dermatol"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"1476793","DOI":"10.3389\/fmed.2024.1476793","article-title":"Successful treatment of refractory palmoplantar pustulosis by upadacitinib: report of 28 patients","volume":"11","author":"Du","year":"2024","journal-title":"Front Med"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1177\/10600280241252688","article-title":"Spesolimab: a review of the first IL-36 blocker approved for generalized pustular psoriasis","volume":"59","author":"Pathak","year":"2024","journal-title":"Ann Pharmacother"}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1518583\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,17]],"date-time":"2025-02-17T00:12:41Z","timestamp":1739751161000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2025.1518583\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,17]]},"references-count":16,"alternative-id":["10.3389\/fmed.2025.1518583"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2025.1518583","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,17]]},"article-number":"1518583"}}